ArticleMedicine2026
Successful treatment of massive stage IIIB cervical cancer with a spindle cell component: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCervical cancer is one of the most common malignancies in women worldwide. Tumors larger than 10 cm in diameter are rarely encountered, and no standard protocol exists for treating them. This case serves as a reference for managing similarly giant tumors and illustrates how a sequential multimodal strategy can downstage the disease. PATIENT CONCERNS: A 33-year-old woman presented with a cervical mass of 14 × 13 × 13 cm, 6 months of intermittent vaginal bleeding, and 1 month of progressive fatigue. DIAGNOSES: Biopsy confirmed stage IIIB cervical squamous cell carcinoma (International Federation of Gynecology and Obstetrics 2021) with a partial spindle cell component.
interventionsBecause of the tumor size, neoadjuvant chemotherapy was given first to reduce tumor burden; concurrent chemoradiotherapy and bevacizumab were then administered. OUTCOMES: Complete remission was achieved after the planned treatment sequence. Imaging at 6 months of follow-up showed no recurrence or metastasis. LESSONS: Individualized sequential multimodal therapy can produce complete remission in massive cervical squamous cell carcinoma. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy plus bevacizumab may be a curative option for selected patients with bulky stage IIIB disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.